KCA
EWTX icon

KVP Capital Advisors’s Edgewise Therapeutics EWTX Stock Holding History

KVP Capital Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.4M Hold
133,000
– – 3.97% 9
2026
Q1 		$4.19M Hold
133,000
– – 3.13% 11
2025
Q4 		$3.3M Buy
+133,000
New +$2.67M 3.19% 13

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KVP Capital Advisors's EWTX Position: Q2 2026 in Review

KVP Capital Advisors held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 133,000 shares worth $5.4M. The position accounts for 3.97% of the portfolio, ranked #9.

KVP Capital Advisors first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • KVP Capital Advisors held 133,000 shares of Edgewise Therapeutics worth $5.4M as of Q2 2026.
  • KVP Capital Advisors left its Edgewise Therapeutics share count unchanged in Q2 2026.
  • Edgewise Therapeutics made up 3.97% of KVP Capital Advisors's portfolio in Q2 2026, its #9 holding.
  • KVP Capital Advisors first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.